The preferential stimulation and resulting uptake of IL-2/IL-15 therapeutic agents by the peripheral blood natural killer (NK) cells may limit the exposure needed to activate CD8+ T cells within the tumor environment,13,14 as intratumoral CD8+ T cells have been associated with efficacy.15 This evidence concerns the gene CD8A and neoplasm.